相关实验视频
Updated: Jul 20, 2025

12:30
Monitoring ER/SR Calcium Release with the Targeted Ca2+ Sensor CatchER+
Published on: May 19, 2017
14.9K
针对调节器作为心力衰竭的治疗方法:专注于肉质网膜的Ca-ATPase
1Division of Applied Medicine, School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea.
Frontiers in cardiovascular medicine
|August 3, 2023
概括
心力衰竭涉及心肌细胞的处理受损,特别是SERCA2a. 本综述探讨了针对SERCA2a的治疗策略,以恢复心脏功能.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 心肌 (Ca2+) 循环受损有助于心力衰竭 (HF) 的发病.
- 心肌细胞的Ca2+处理由诸如质网膜Ca2+ ATPase (SERCA2a) 之类的蛋白质调节.
- 减少SERCA2a表达/活性是高心力衰竭的标志,影响心脏放松和收缩能力.
研究的目的:
- 审查SERCA2a的监管机制.
- 探索针对SERCA2a的潜在治疗策略,用于治疗HF.
主要方法:
- 临床前和临床研究的文献综述.
- 对SERCA2a监管途径的分析.
主要成果:
- SERCA2a对于扩张性Ca2+重新吸收到sarcoplasmic网膜至关重要.
- 降低SERCA2a功能会通过破坏放松和Ca2+恢复而加剧HF.
- 目前正在研究针对SERCA2a的各种治疗方法.
结论:
- 恢复SERCA2a功能是心力衰竭的一个有希望的治疗途径.
- 向SERCA2a可能会改善心脏收缩功能并逆转结构重塑.
- 在临床前和临床环境中正在进行的研究旨在验证基于SERCA2a的疗法.
相关概念视频
Heart Failure Drugs: Inotropic Agents
625
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
625
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
565
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
565
Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
ATP Driven Pumps II: P-type Pumps
4.9K
The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V.
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
4.9K

